Cabozantinib market launch price forecast in 2025

Cabozantinib is a broad-spectrum tyrosine kinase inhibitor that targets multiple signaling pathways related to tumor proliferation and metastasis, including MET, VEGFR, RET, and AXL. It has been approved in many countries for the treatment of advanced kidney cancer, medullary thyroid cancer and hepatocellular carcinoma, showing clear clinical value especially in patients who have failed to respond or are resistant to standard treatments. The therapeutic effect of cabozantinib is not only reflected in tumor control, but also in that its multi-target mechanism provides the potential to inhibit metastasis and microenvironment. It is one of the important choices for the treatment of many refractory tumors.

Up to now, the original drug of cabozantinib has not been officially launched in mainland China, and clinical use mainly relies on patients to obtain it through overseas drug purchase channels. In the Chinese market, although there is no clear launch price, according to industry speculation, the price of cabozantinib tablets such as 20mg30 tablets, 40mg30 tablets and 60mg*30 tablets is expected to be around RMB 50,000 per box, which may fluctuate slightly depending on international logistics, taxes and channel services. In the international market, cabozantinib has been approved for use in Japan, Europe, Turkey and other places. The price of tablets is roughly equivalent to about 30,000 yuan, and the price of capsule preparations is about 40,000 yuan. This is directly related to the dosage form, packaging specifications and the coverage of the national medical insurance system.

It is worth noting that due to the high price of the original drug, many countries and regions have launched generic versions of cabozantinib, especially in countries with relatively mature generic drug markets such as Laos, Bangladesh and India. For example, cabozantinib (20mg*90 tablets) produced by Laos United Pharmaceuticals is sold for as low as RMB 100, which greatly reduces the economic burden. Although these generic drugs have not been approved by China's State Food and Drug Administration, they have shown similar efficacy and safety to the original drugs in many overseas clinical practices. Therefore, many patients obtain such drugs through overseas medical institutions for disease control.

Reference:https://en.wikipedia.org/wiki/Cabozantinib